Skip to main content
SpringerLink
Log in

Pathological approach to evolving prognostic and predictive factors of breast cancer

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Among the evolving concepts of prognostic and predictive factors in breast carcinoma pathology are those relating to lymph node status, tumor size, histological type, histological grade, bone marrow micrometastasis, and lymphatic and blood vessel involvement. Correct identification based on a uniform and complete pathological evaluation of tumor specimens is vital to correctly decide treatment. In addition we describe inflammatory cell infiltrates in breast carcinoma as not only prognostic and predictive factors but also pleiotropic regulators and/or effectors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clark GM: Prognostic and predictive factors. Harris JR, Lippmann ME, eds, Diseases of the breast, 2nd ed, Liiponcott Williams and Wilkins, Philadelphia, pp489–514, 2000.

    Google Scholar 

  2. Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic factors: when is“statistically significant” clinically useful?Breast Cancer Res Treat 52: 305–319 1998.

    Article  PubMed  CAS  Google Scholar 

  3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Thera py of Primary Breast Cancer.J Clin Oncol 19:3817- 3827, 2001.

    PubMed  CAS  Google Scholar 

  4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: updated international expert consensus on the primary thera- py of early breast cancer.J Clin Oncol 21:3357–3365, 2003.

    Article  PubMed  Google Scholar 

  5. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 mono- clonal antibody in women who have HER2-overex- pressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 17:2639–2648, 1999.

    PubMed  CAS  Google Scholar 

  6. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase H study of receptor- enhanced chemosensitivity using recombinant huma- nized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.J Clin Oncol 16:2659–2671, 1998.

    PubMed  CAS  Google Scholar 

  7. Yamauchi H, Stearns V, Hayes DF: The Role of c- erbB-2 as a predictive factor in breast cancer.Breast Cancer 8:171–183, 2001.

    Article  PubMed  CAS  Google Scholar 

  8. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB- 2 as a predictive factor in breast cancer.J Clin Oncol 19:2334–2356, 2001.

    PubMed  CAS  Google Scholar 

  9. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.Arch Pathol Lab Med 124:966–978, 2000.

    PubMed  CAS  Google Scholar 

  10. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet 339:1–15, 71–85, 1992.

    Google Scholar 

  11. Fukutomi T, Akashi-Tanaka S: Prognostic and predictive factors in the adjuvant treatment of breast cancer.Breast Cancer 9:95–99, 2002.

    Article  PubMed  Google Scholar 

  12. Weaver DL: Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant?Am J Surg Pathol 27:842–845, 2003.

    Article  PubMed  Google Scholar 

  13. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, Peterse JL, Mukai K, Tabar L, Jacquemier J, Cornelisse CJ, Sasco R, Pisani P, Goldgar DE, Devilee P, Cleton-Jansen MJ, BorresenDale AL, van’tVeer L, Sapino A: Invasive breast carcinoma. Tavassoli FA, Devilee P, eds, World Health Organisation Classification of Tumours, Pathology and Genetics, Tumours of the Breast and Female Genital Organs, IARCPress, Lyon, ppl3–59, 2003.

    Google Scholar 

  14. de Mascarel I, Bonichon F, Coindre JM, Trojani M: Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up.Br J Cancer 66:523–527, 1992.

    PubMed  Google Scholar 

  15. International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers.Lancet 335:1565- 1568, 1990.

    Google Scholar 

  16. Rosen PP: Invasive duct carcinoma. Rosen PP ed, Rosen’s breast pathology, 2nd ed, Lippincott Williams and Wilkins, Philadelphia, pp325–364, 2001.

    Google Scholar 

  17. Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL: Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.Cancer 83:2502–2508, 1998.

    Article  PubMed  CAS  Google Scholar 

  18. AJCC: AJCC Cancer Staging Manual. 6th ed, Springer Verlag, New York, 2002.

    Google Scholar 

  19. Page DL: Special types of invasive breast cancer, with clinical implications.Am J Surg Pathol 27:832–835, 2003.

    Article  PubMed  Google Scholar 

  20. Stalsberg H, Hartmann WH: The delimitation of tubular carcinoma of the breast.Hum Pathol 31:601–607, 2000.

    Article  PubMed  CAS  Google Scholar 

  21. Baker RR: Unusual lesions and their management.Surg Clin North Am 70:963–975, 1990.

    PubMed  CAS  Google Scholar 

  22. Bratthauer GL, Moinfar F, Stamatakos MD, Mezzetti TP, Shekitka KM, Man YG, Tavassoli FA: Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.Hum Pathol 33:620–627, 2002.

    Article  PubMed  CAS  Google Scholar 

  23. Clayton F: Pure mucinous carcinomas of breast: morphologic features and prognostic correlates.Hum Pathol 17:34–38, 1986.

    Article  PubMed  CAS  Google Scholar 

  24. De La Cruz C, Moriya T, Endoh M, Watanabe M, Takeyama J, Yang M, Oguma M, Sakamoto K, Suzuki T, Hirakawa H, Orita Y, Ohuchi N, Sasano H: Invasive micropapillary carcinoma of the breast: Clinicopathological and immunohistochemical study.Pathol Int 54:90–96, 2004.

    Article  Google Scholar 

  25. Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL: Metaplastic breast tumors with a dominant fibromatosis -like phenotype have a high risk of local recurrence.Cancer 85:2170–2182, 1999.

    Article  PubMed  CAS  Google Scholar 

  26. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA: The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.Cancer 83:1529–1539, 1998.

    Article  PubMed  CAS  Google Scholar 

  27. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.Histopathology 19:403–410, 1991.

    Article  PubMed  CAS  Google Scholar 

  28. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blarney RW, Robertson JF, Ellis IO: Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma.Histopathology 27:219–226, 1995.

    Article  PubMed  CAS  Google Scholar 

  29. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer.J Clin Oncol 20:3628–3636, 2002.

    Article  PubMed  Google Scholar 

  30. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T: Establishment of histological criteria for high-risk node-negative breast carcinoma for a multiinstitutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section.Jpn J Clin Oncol 28:486–491, 1998.

    Article  PubMed  CAS  Google Scholar 

  31. Tsuda H, Takarabe T, Akashi-Tanaka S, Fukutomi T, Nanasawa T, Watanabe T: Evaluation of histopathological criteria for identifying node-negative breast cancer with high risk of early recurrence in the NSAS-BC protocol study.Breast Cancer 7:201–209, 2000.

    Article  PubMed  CAS  Google Scholar 

  32. Rosen PP: Pathologic examination of breast and lymph node specimens. Rosen PP ed, Rosen’s breast pathology, 2nd ed, Lippincott Williams and Wilkins, Philadelphia, pp931–990, 2001.

    Google Scholar 

  33. Arihiro K, Inai K: Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma.Pathol Int; 51:100–106, 2001.

    Article  PubMed  CAS  Google Scholar 

  34. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RV: Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).Cancer 76:2266–2274, 1995.

    Article  PubMed  CAS  Google Scholar 

  35. Lee AK, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.Cancer 79:761–771, 1997.

    Article  PubMed  CAS  Google Scholar 

  36. Chen YY, Schnitt SJ: Prognostic factors for patients with breast cancers 1 cm and smaller.Breast Cancer Res Treat 51:209–225, 1998.

    Article  PubMed  CAS  Google Scholar 

  37. Pinder SE, Ellis IO, Galea M, O’Rouke S, Blarney RW, Elston CW: Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up.Histopathology 24:41–47, 1994.

    Article  PubMed  CAS  Google Scholar 

  38. Fein DA, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER, Jardines LA, Eisenberg BL: Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes.J Surg Oncol 65:34- 39, 1997.

    Article  PubMed  CAS  Google Scholar 

  39. Barth A, Craig PH, Silverstein MJ: Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.Cancer 79:1918–1922, 1997.

    Article  PubMed  CAS  Google Scholar 

  40. Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast.J Clin Oncol 8:1457–1465, 1990.

    PubMed  CAS  Google Scholar 

  41. Arihiro K, Kaneko M, Fujii S, Inai K: Loss of CD9 with Expression of CD31 and VEGF in Breast Carcinoma, as Predictive Factors of Lymph Node Metastasis.Breast Cancer 5:131–138, 1998.

    Article  PubMed  Google Scholar 

  42. Jacquemier J, Mathoulin-Portier MP, Valtola R, Charafe -Jauffret E, Geneix J, Houvenaeghel G, Puig B, Bardou VJ, Hassoun J, Viens P, Birnbaum D: Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial -growth-factor receptor 3.Int J Cancer 89:69–73, 2000.

    Article  PubMed  CAS  Google Scholar 

  43. Stenkvist B, Bengtsson E, Dahlqvist B, Eklund G, Eriksson O, Jarkrans T, Nordin B: Predicting breast cancer recurrence.Cancer 50:2884–2893, 1982.

    Article  PubMed  CAS  Google Scholar 

  44. Lee AH, Happerfield LC, Millis RR, Bobrow LG: Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast.Br J Cancer 74:796–801, 1996.

    PubMed  CAS  Google Scholar 

  45. Nixon AJ, Schnitt SJ, Gelman R, Gage I, Bornstein B, Hetelekidis S, Recht A, Silver B, Harris JR, Connolly JL: Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy.Cancer 78:1426–1431, 1996.

    Article  PubMed  CAS  Google Scholar 

  46. O’Sullivan C, Lewis CE: Tumour-associated leucocytes: friends or foes in breast carcinoma.J Pathol 172:229–235, 1994.

    Article  PubMed  CAS  Google Scholar 

  47. Conboy IM, DeKruyff RH, Tate KM, Cao ZA, Moore TA, Umetsu DT, Jones PP: Novel genetic regulation of T helper 1 (Th1)/Th2 cytokine production and encephalitogenicity in inbred mouse strains.J Exp Med 185:439–451, 1997.

    Article  PubMed  CAS  Google Scholar 

  48. Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A, Basolo F: Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.Br J Cancer 80:579–584, 1999.

    Article  PubMed  CAS  Google Scholar 

  49. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A: Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.Cancer 88:2061–2071, 2000.

    Article  PubMed  CAS  Google Scholar 

  50. Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D: Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome.Int J Cancer 84:309–314, 1999.

    Article  PubMed  CAS  Google Scholar 

  51. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.J Exp Med 190:1417–1426, 1999.

    Article  PubMed  CAS  Google Scholar 

  52. Hillenbrand EE, Neville AM, Coventry BJ: Immunohistochemical localization of CD la-positive putative dendritic cells in human breast tumours.Br J Cancer 79:940–944, 1999.

    Article  PubMed  CAS  Google Scholar 

  53. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas.Int J Cancer 104:92–97, 2003.

    Article  PubMed  CAS  Google Scholar 

  54. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer.Clin Cancer Res 3:483–490, 1997.

    PubMed  CAS  Google Scholar 

  55. Banchereau J, Steinman RM: Dendritic cells and the control of immunity.Nature 392:245–252, 1998.

    Article  PubMed  CAS  Google Scholar 

  56. Medley QG, Kedersha N, O’Brien S, Tian Q, Schlossman SF, Streuli M, Anderson P: Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition.Proc Natl Acad Sci USA 93:685- 689, 1996.

    Article  PubMed  CAS  Google Scholar 

  57. Griffiths GM, Mueller C: Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells.Immunol Today 12:415–419, 1991.

    Article  PubMed  CAS  Google Scholar 

  58. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB: Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.Mod Pathol 12:1050–1056, 1999.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomical Pathology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734–8551, Hiroshima, Japan

    Koji Arihiro

Authors
  1. Koji Arihiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Arihiro.

About this article

Cite this article

Arihiro, K. Pathological approach to evolving prognostic and predictive factors of breast cancer. Breast Cancer 11, 343–349 (2004). https://doi.org/10.1007/BF02968041

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968041

Key words

Search

Navigation